Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (71-80 of 459) with videos related to

Pageof 46
Sort By:
Expert Review of Molecular Diagnostics|November 20, 2018
Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapyAlessia Cimadamore, Marina Scarpelli, Matteo Santoni, et al.
European Urology Oncology|August 15, 2019
Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the EndFrancesco Massari, Vincenzo Di Nunno, Matteo Santoni, et al.
Journal of Neuroinflammation|February 4, 2015
Danger- and pathogen-associated molecular patterns recognition by pattern-recognition receptors and ion channels of the transient receptor potential family triggers the inflammasome activation in immune cells and sensory neuronsGiorgio Santoni, Claudio Cardinali, Maria Beatrice Morelli, et al.
Expert Opinion on Pharmacotherapy|August 18, 2021
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinomaAndrea Marchetti, Matteo Rosellini, Alessandro Rizzo, et al.
International Journal of Cancer|October 12, 2013
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitorMatteo Santoni, Rossana Berardi, Consuelo Amantini, et al.
Tumori|May 20, 2022
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysisMatteo Santoni, Francesco Massari, Alessandro Rizzo, et al.
Current Urology Reports|January 29, 2015
Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literatureDaniele Minardi, Luigi Quaresima, Matteo Santoni, et al.
Frontiers in Bioengineering and Biotechnology|May 17, 2021
Agent-Based Learning Model for the Obesity Paradox in RCCMatteo Belenchia, Giacomo Rocchetti, Stefano Maestri, et al.
Expert Opinion on Investigational Drugs|December 19, 2025
Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years?Linda Danielli, Matteo Rosellini, Elisa Tassinari, et al.
Diagnostics (Basel, Switzerland)|May 14, 2025
From Morphology to Gene Expression Profiling in Mycosis Fungoides: Is It Still a Diagnostic Challenge?Alessandra Filosa, Gerardo Cazzato, Elisa Bartoli, et al.
Pageof 46

Showing results (71-80 of 459) with videos related to

Sort By:
Pageof 46
Expert Review of Molecular Diagnostics|November 20, 2018
Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapyAlessia Cimadamore, Marina Scarpelli, Matteo Santoni, et al.
European Urology Oncology|August 15, 2019
Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the EndFrancesco Massari, Vincenzo Di Nunno, Matteo Santoni, et al.
Journal of Neuroinflammation|February 4, 2015
Danger- and pathogen-associated molecular patterns recognition by pattern-recognition receptors and ion channels of the transient receptor potential family triggers the inflammasome activation in immune cells and sensory neuronsGiorgio Santoni, Claudio Cardinali, Maria Beatrice Morelli, et al.
Expert Opinion on Pharmacotherapy|August 18, 2021
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinomaAndrea Marchetti, Matteo Rosellini, Alessandro Rizzo, et al.
International Journal of Cancer|October 12, 2013
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitorMatteo Santoni, Rossana Berardi, Consuelo Amantini, et al.
Tumori|May 20, 2022
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysisMatteo Santoni, Francesco Massari, Alessandro Rizzo, et al.
Current Urology Reports|January 29, 2015
Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literatureDaniele Minardi, Luigi Quaresima, Matteo Santoni, et al.
Frontiers in Bioengineering and Biotechnology|May 17, 2021
Agent-Based Learning Model for the Obesity Paradox in RCCMatteo Belenchia, Giacomo Rocchetti, Stefano Maestri, et al.
Expert Opinion on Investigational Drugs|December 19, 2025
Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years?Linda Danielli, Matteo Rosellini, Elisa Tassinari, et al.
Diagnostics (Basel, Switzerland)|May 14, 2025
From Morphology to Gene Expression Profiling in Mycosis Fungoides: Is It Still a Diagnostic Challenge?Alessandra Filosa, Gerardo Cazzato, Elisa Bartoli, et al.
Pageof 46